From: Antimicrobial activity of some sulfonamide derivatives on clinical isolates of Staphylococus aureus
Antimicrobials | Inhibition zone diameter (mm)a | Zone diameter (mm) | Tested S. aureus clinical isolates | ||||||
---|---|---|---|---|---|---|---|---|---|
Susceptibility range (%) (n = 50)b | |||||||||
Name | Concentration (μg) | R | I | S | Range | Median | R | I | Sc |
Oxacillin | 1 μg | ≤10 | 11–12 | ≥13 | 0–23 | 11.5 | 30(60) | 0 | 20(40) |
Trimetoprim (SXT) | 25 μg | ≤10 | 11–15 | ≥16 | 21.5–32.5 | 27 | 0 | 0 | 50(100) |
Compound I | 500 μg | ≤12 | 13–16 | ≥17 | 12–28 | 20 | 1(2) | 7(14) | 42(84) |
Compound II | 500 μg | ≤12 | 13–16 | ≥17 | 11–25 | 18 | 3(6) | 22(44) | 25(50) |
Compound III | 500 μg | ≤12 | 13–16 | ≥17 | 11–19 | 15 | 13(26) | 19(38) | 18(36) |
Compound IV | 500 μg | ≤12 | 13–16 | ≥17 | 0–11 | 5.5 | 50(100) | 0 | 0 |